Abstract |
Expression of the neuroendocrine peptide calcitonin (CT) and its receptor (CTR) is frequently elevated in prostate cancers (PCs), and activation of the CT-CTR axis in non-invasive PC cells induces an invasive phenotype. We aimed to link CT/CTR expression in prostate specimens to clinicopathological parameters of PC. We analyzed CT and CTR expression in cohorts of benign prostates and primary PCs with/without metastatic disease by immunohistochemistry. Furthermore, we correlated CT/CTR expression with several clinicopathological parameters. CT/CTR immunostaining in benign prostate acini was predominantly localized to basal epithelium. However, this spatial specificity was lost in malignant prostates. PC sections displayed a remarkable increase in cell populations expressing CT/CTR and their staining intensity. Tumors with higher CT/CTR expression consistently displayed metastatic disease and poor clinical outcome. High CT/CTR expression in primary prostate tumors may serve as a prognostic indicator of disease aggressiveness and poor clinical outcome.
|
Authors | Arvind Thakkar, Irene V Bijnsdorp, Albert A Geldof, Girish V Shah |
Journal | Oncology reports
(Oncol Rep)
Vol. 30
Issue 3
Pg. 1265-74
(Sep 2013)
ISSN: 1791-2431 [Electronic] Greece |
PMID | 23820954
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Receptors, Calcitonin
- Calcitonin
|
Topics |
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(metabolism)
- Calcitonin
(metabolism)
- Cohort Studies
- Fluorescent Antibody Technique
- Follow-Up Studies
- Humans
- Immunoenzyme Techniques
- Male
- Middle Aged
- Neoplasm Grading
- Neoplasm Metastasis
- Neoplasm Staging
- Prognosis
- Prostate
(metabolism, pathology)
- Prostatic Hyperplasia
(metabolism, mortality, pathology)
- Prostatic Neoplasms
(metabolism, mortality, pathology)
- ROC Curve
- Receptors, Calcitonin
(metabolism)
- Survival Rate
- Tissue Array Analysis
|